SEARCH

Search Details

Mori Takashi

Hokkaido University Hospital　Central Clinical Facilities　RadiologyAssistant Professor

Researcher basic information

■ Degree
  • 博士（医学）, 北海道大学
  • 修士（工学）, 東京大学
■ URL
researchmap URLホームページURL■ Various IDs
J-Global ID■ Research Keywords and Fields
Research Field
  • Life Science, Radiological sciences
■ Educational Organization

Research activity information

■ Papers
  • Three cases of whole breast irradiation for breast cancer in patients with Lymphangioleiomyomatosis (LAM)
    Rumiko Kinoshita; Mitsuchika Hosoda; Fumi Kato; Hirokazu Kimura; Kaoruko Shimizu; Takashi Mori; Kentaro Nishioka; Takayuki Hashimoto; Masato Takahashi; Satoshi Konno; Hidefumi Aoyama
    Breast Cancer, Springer Science and Business Media LLC, 03 Mar. 2026, [Peer-reviewed]
    Scientific journal
  • Effect of Mouthpiece Materials for Proton Therapy of Head and Neck Cancer With an Investigation of Material Suitability
    Masaaki Suzuka; Takashi Mori; Shigeru Yamano; Akiko Takeuchi; Tomoka Shima; Koichi Yasuda; Yurika Kinoshita; Keiji Nakazato; Hideki Minatogawa; Yasuhiro Dekura; Masayoshi Tomita; Hidefumi Aoyama; Kazuyuki Minowa
    Oral Science International, 23, 2, Wiley, 11 Feb. 2026, [Peer-reviewed], [Corresponding author]
    Scientific journal, ABSTRACT

    Aim

    To investigate the effect and suitability of mouthpiece materials for proton therapy (PT) of head and neck cancer (HNC).

    Methods

    Computed tomography (CT) numbers and the stopping power ratios (SPRs) of six dental materials were measured. The SPRs were converted to CT numbers, and the materials with the highest, lowest, and closest to the CT numbers of surrounding normal tissue were identified. To investigate how mouthpiece CT numbers affect the dose distribution for HNC, treatment plans of 17 patients were recalculated by changing the mouthpiece CT numbers to these three CT numbers, and doses to normal tissues were measured.

    Results

    Vinyl polysiloxane had the highest CT number, and thermoplastic ethylene vinyl acetate copolymer splints had the lowest CT number. Temporary relining resin had the CT number closest to normal tissue. Temporary relining resin had the smallest difference in the CT of the CT image, and the CT converted from SPR. The plans of temporary relining resin did not differ significantly from the actual plan, and the patient with the largest dose difference had a 1.75 gray equivalent (GyE) in the mandible max dose. However, that of vinyl polysiloxane and that of thermoplastic ethylene vinyl acetate copolymer splints differed significantly from the actual plans in several of the measured items, with the maximum difference of 5.43 GyE in the oral mean dose.

    Conclusion

    We confirmed that changing the material of the mouthpiece could cause the dose to normal tissues to vary by approximately 5 GyE.
  • Primary spinal cord malignant B-cell lymphoma successfully treated with tirabrutinib at relapse: a case report.
    Yukitomo Ishi; Hiroaki Motegi; Soichiro Takamiya; Ai Shimizu; Takashi Mori; Sogo Oki; Motoyuki Iwasaki; Shigeru Yamaguchi; Miki Fujimura
    European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 17 Nov. 2025, [International Magazine]
    English, Scientific journal
  • Evaluation of intra‐fractional target displacement by patient motion during a single‐isocenter multi‐target stereotactic radiation therapy for brain metastases
    Ryota Yamada; Takaaki Yoshimura; Ryo Murata; Kentaro Nishioka; Takashi Mori; Fuki Koizumi; Yoshihiro Fujita; Shuhei Takahashi; Takahiro Hattori; Takahiro Kanehira; Kohei Yokokawa; Rie Yamazaki; Kenji Horita; Hiroshi Tamura; Yamato Wakabayashi; Yuta Ichiu; Takayuki Hashimoto; Hidefumi Aoyama
    Journal of Applied Clinical Medical Physics, 26, 9, Wiley, 21 Aug. 2025, [Peer-reviewed]
    Scientific journal, Abstract

    Background

    Single‐isocenter multi‐target volumetric modulated arc therapy (SIMT‐VMAT) has been implemented widely in fractionated stereotactic radiosurgery (fSRS) to treat brain metastases. The impact of rotational intra‐fractional patient motion (IFPM) is influenced by the distance between the geometric target's center and the isocenter (DTI).

    Purpose

    We hypothesized that IFPM's impact on each target would increase with greater DTI during fSRS. Therefore, we aimed to estimate the intra‐fractional target displacement (IFTD), which represents each target's displacement caused by translational and rotational components of IFPM.

    Methods

    In this study, we involved 35 patients with 2–13 brain metastases, all of whom had previously undergone SIMT‐VMAT fSRS. All patients were immobilized using a clamshell‐style device, with 28 using a biteplate. Cone beam computed tomography (CBCT) images were obtained at the same imaging center before and after treatment. The IFPM was calculated using both CBCT datasets. The IFTD was determined by comparing the planned target coordinates with the actual coordinates while factoring in IFPM.

    Results

    We evaluated 136 targets. The mean IFTD was 0.38 mm (95% confidence interval [CI]: 0.37–0.40 mm) with the biteplate and 0.65 mm (95% CI: 0.59–0.71 mm) without it. A very weak positive correlation was observed between DTI and IFTD despite the immobilization method. This correlation indicates that the distance dependence of IFTD is nearly negligible.

    Conclusion

    The findings showed that the impact of IFPM on each target demonstrated minimal dependence on the DTI. Displacement was relatively consistent regardless of the target location. In addition, the use of a biteplate was suggested to potentially reduce these effects.
  • Assessment of prognostic value and development of predictive model for prolonged lymphopenia in patients with glioblastoma following chemoradiotherapy
    Shuhei Takahashi; Kentaro Nishioka; Takashi Mori; Shigeru Yamaguchi; Yukitomo Ishi; Keiji Kobashi; Yoichi M Ito; Zen-ichi Tanei; Hiromi Kanno-Okada; Shinya Tanaka; Hidefumi Aoyama
    Journal of Radiation Research, Oxford University Press (OUP), 11 Aug. 2025, [Peer-reviewed]
    Scientific journal, ABSTRACT

    Lymphopenia during chemoradiotherapy (CRT) for glioblastoma has been shown to be a poor prognostic factor. However, the relationship between prolonged lymphopenia (PL) after CRT and prognosis remains unclear. This study aimed to explore the relationship between PL and glioblastoma prognosis and develop a predictive model for PL risk. We analyzed 87 patients with primary glioblastoma who underwent postoperative CRT with 60 Gy in 30 fractions of radiotherapy and temozolomide. PL was defined as grade 2 or higher lymphopenia 1 month after the completion of CRT. We conducted survival analysis, identified risk factors for PL, and developed a predictive model for PL risk. Of the 87 patients, 41 developed PL, and progression-free survival (PFS) was significantly shorter in the PL group (median 8.0 months vs 15.4 months, P = 0.003). However, there was no significant difference in overall survival between the two groups. PL was also a significant factor for shorter PFS in multivariable analysis (P = 0.040). Brain V20Gy (percentage of brain volume receiving ≥20 Gy), gross total resection (GTR), and preoperative Karnofsky performance status (KPS) were identified as significant risk factors for PL. The predictive model showed that the risk of PL could be predicted by brain V20Gy, sex, age, GTR and preoperative KPS. PL was identified as a PFS shortening factor. Our model suggests that reducing irradiated brain volume may help prevent PL and could potentially improve glioblastoma prognosis by preserving cancer immunity.
  • Recurrence patterns and clinical outcomes in adult cerebellar glioblastoma
    Sogo Oki; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Masayuki Gekka; Zen-ichi Tanei; Hiromi Kanno-Okada; Emi Takakuwa; Satoshi Tanaka; Takashi Mori; Kentaro Nishioka; Hidefumi Aoyama; Shinya Tanaka; Miki Fujimura
    Acta Neurochirurgica, 167, 1, Springer Science and Business Media LLC, 08 Aug. 2025, [Peer-reviewed]
    Scientific journal
  • Clinical Outcomes of Fractionated Radiation Therapy for Spinal Intramedullary Arteriovenous Malformations: A Single Institutional Retrospective Review
    Ruja Vichitvejpaisal; Kentaro Nishioka; Toshiya Osanai; Motoyuki Iwasaki; Takashi Mori; Yusuke Uchinami; Tomohiko Miyazaki; Fuki Koizumi; Takayuki Hashimoto; Miki Fujimura; Hidefumi Aoyama
    Advances in Radiation Oncology, 101778, 101778, Elsevier BV, Mar. 2025, [Peer-reviewed]
    Scientific journal
  • Long-term outcome and social-intellectual ability of patients with basal ganglia germinoma
    Michinari Okamoto; Shigeru Yamaguchi; Ryosuke Sawaya; Yukitomo Ishi; Hiroaki Motegi; Yukayo Terashita; Minako Sugiyama; Yuko Cho; Kentaro Nishioka; Takashi Mori; Takayuki Hashimoto; Hidefumi Aoyama; Atsushi Manabe; Miki Fujimura
    Pediatric Neurology, Elsevier BV, Jan. 2025
    Scientific journal
  • Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
    Miho Sato; Takahiro Osawa; Kentaro Nishioka; Tomohiko Miyazaki; Shuhei Takahashi; Takashi Mori; Takayuki Hashimoto; Haruka Miyata; Ryuji Matsumoto; Takashige Abe; Kazuki Ohashi; Sachiyo Murai; Yoichi M Ito; Nobuo Shinohara
    International journal of urology : official journal of the Japanese Urological Association, 09 Oct. 2024, [International Magazine]
    English, Scientific journal, OBJECTIVES: To determine how the treatment decision-making process and posttreatment health-related quality of life (HRQOL) are related to regret about treatment choice for prostate cancer patients in Japan. METHODS: We invited a total of 614 patients who were treated with radiation therapy (RT), radical prostatectomy (RP), or active surveillance/watchful waiting (AS/WW) from April 2007 to March 2021. Posttreatment regret was evaluated by the Decision Regret Scale. HRQOL was evaluated by the Expanded Prostate Cancer Index Composite and the 12-item Short Form Survey. The decision-making process was assessed by patient evaluation of the decision-making process. We compared the decision regret scale scores across treatment types, HRQOL, and decision-making processes. RESULTS: Data from 371 patients were analyzed (RT: 202, RP: 149, AS/WW: 20). The median length of time since treatment was 64 (IQR: 43-93) months. The decision regret scale scores were not significantly different among the treatment groups but were significantly greater (strong regret) in patients with poor urinary summary scores, bowel summary scores, and hormonal summary scores. The decision regret scale scores were significantly lower (less regret) for patients who reported being adequately informed at the time of the treatment decision and who had adequately communicated their questions and concerns to physicians than for patients who reported less adequate communication. This result was also observed among patients who reported low HRQOL scores. CONCLUSIONS: These findings underline the important influence of posttreatment HRQOL and decision-making as an interactive process between physicians and their patients on posttreatment regret in prostate cancer patients.
  • A simulation study of MR-guided proton therapy system using iron-yoked superconducting open MRI: a conceptual study.
    Yusuke Fujii; Hideaki Ueda; Taisuke Takayanagi; Kentaro Nishioka; Takashi Mori; Takayuki Hashimoto; Hidefumi Aoyama; Kikuo Umegaki; Taeko Matsuura
    Journal of radiation research, 04 Oct. 2024, [International Magazine]
    English, Scientific journal, Radiotherapy platforms integrated with magnetic resonance imaging (MRI) have been significantly successful and widely used in X-ray therapy over the previous decade. MRI provides greater soft-tissue contrast than conventional X-ray techniques, which enables more precise radiotherapy with on-couch adaptive treatment planning and direct tracking of moving tumors. The integration of MRI into a proton beam irradiation system (PBS) is still in the research stage. However, this could be beneficial as proton therapy is more sensitive to anatomical changes and organ motion. In this simulation study, we considered the integration of PBS into the 0.3-T superconducting open MRI system. Our proposed design involves proton beams traversing a hole at the center of the iron yoke, which allows for a reduced fringe field in the irradiation nozzle while maintaining a large proton scan field of the current PBS. The shape of the bipolar MRI magnets was derived to achieve a large MRI field-of-view. To monitor the beam position and size accurately while maintaining a small beam size, the beam monitor installation was redesigned from the current system. The feasibility of this system was then demonstrated by the treatment plan quality, which showed that the magnetic field did not deteriorate the plan quality from that without the magnetic field for both a rectangular target and a prostate case. Although numerous challenges remain before the proposed simulation model can be implemented in a clinical setting, the presented conceptual design could assist in the initial design for the realization of the MR-guided proton therapy.
  • 前立腺がん患者における治療決定時の意思決定プロセスと治療後の後悔との関連
    佐藤 三穂; 大澤 崇宏; 宮田 遥; 松本 隆児; 安部 崇重; 西岡 健太郎; 宮崎 智彦; 高橋 周平; 森 崇; 橋本 孝之; 大橋 和貴; 村井 祥代; 伊藤 陽一; 篠原 信雄
    日本癌治療学会学術集会抄録集, 62回, YOA O22, 5, (一社)日本癌治療学会, Oct. 2024
    Japanese
  • Geometric target margin strategy of proton craniospinal irradiation for pediatric medulloblastoma.
    Takaaki Yoshimura; Keigo Kondo; Takayuki Hashimoto; Kentaro Nishioka; Takashi Mori; Takahiro Kanehira; Taeko Matsuura; Seishin Takao; Hiroshi Tamura; Takuya Matsumoto; Kenneth Sutherland; Hidefumi Aoyama
    Journal of radiation research, 15 Sep. 2024, [International Magazine]
    English, Scientific journal, In proton craniospinal irradiation (CSI) for skeletally immature pediatric patients, a treatment plan should be developed to ensure that the dose is uniformly delivered to all vertebrae, considering the effects on bone growth balance. The technical (t) clinical target volume (CTV) is conventionally set by manually expanding the CTV from the entire intracranial space and thecal sac, based on the physician's experience. However, there are differences in contouring methods among physicians. Therefore, we aimed to propose a new geometric target margin strategy. Nine pediatric patients with medulloblastoma who underwent proton CSI were enrolled. We measured the following water equivalent lengths for each vertebra in each patient: body surface to the dorsal spinal canal, vertebral limbus, ventral spinal canal and spinous processes. A simulated tCTV (stCTV) was created by assigning geometric margins to the spinal canal using the measurement results such that the vertebral limb and dose distribution coincided with a margin assigned to account for the uncertainty of the proton beam range. The stCTV with a growth factor (correlation between body surface area and age) and tCTV were compared and evaluated. The median values of each index for cervical, thoracic and lumber spine were: the Hausdorff distance, 9.14, 9.84 and 9.77 mm; mean distance-to-agreement, 3.26, 2.65 and 2.64 mm; Dice coefficient, 0.84, 0.81 and 0.82 and Jaccard coefficient, 0.50, 0.60 and 0.62, respectively. The geometric target margin setting method used in this study was useful for creating an stCTV to ensure consistent and uniform planning.
  • 当院における仙骨脊索腫に対する陽子線治療の後方視的検討
    檜垣 朔; 田口 大志; 宮崎 智彦; 森 崇; 西岡 健太郎; 加藤 徳雄; 橋本 孝之; 田村 昌也; 高尾 聖心; 松浦 妙子; 青山 英史
    日本医学放射線学会秋季臨床大会抄録集, 60回, S442, S442, (公社)日本医学放射線学会, Sep. 2024
    Japanese
  • Quality of palliative radiotherapy assessed using quality indicators: a multicenter survey†.
    Tetsuo Saito; Naoto Shikama; Takeo Takahashi; Naoki Nakamura; Takashi Mori; Kaori Nakajima; Masahiko Koizumi; Shuhei Sekii; Takeshi Ebara; Hiroki Kiyohara; Keiko Higuchi; Atsunori Yorozu; Takeshi Nishimura; Yasuo Ejima; Hideyuki Harada; Norio Araki; Misako Miwa; Kazunari Yamada; Terufumi Kawamoto; Nobuki Imano; Joichi Heianna; Miwako Nozaki; Yuki Wada; Yu Ohkubo; Nobue Uchida; Miho Watanabe; Takashi Kosugi; Kazunari Miyazawa; Shigeo Yasuda; Hiroshi Onishi
    Journal of radiation research, 65, 4, 532, 539, 22 Jul. 2024, [International Magazine]
    English, Scientific journal, We sought to identify potential evidence-practice gaps in palliative radiotherapy using quality indicators (QIs), previously developed using a modified Delphi method. Seven QIs were used to assess the quality of radiotherapy for bone metastases (BoM) and brain metastases (BrM). Compliance rate was calculated as the percentage of patients for whom recommended medical care was conducted. Random effects models were used to estimate the pooled compliance rates. Of the 39 invited radiation oncologists, 29 (74%) from 29 centers participated in the survey; 13 (45%) were academic and 16 (55%) were non-academic hospitals. For the QIs, except for BoM-4, the pooled compliance rates were higher than 80%; however, for at least some of the centers, the compliance rate was lower than these pooled rates. For BoM-4 regarding steroid use concurrent with radiotherapy for malignant spinal cord compression, the pooled compliance rate was as low as 32%. For BoM-1 regarding the choice of radiation schedule, the compliance rate was higher in academic hospitals than in non-academic hospitals (P = 0.021). For BrM-3 regarding the initiation of radiotherapy without delay, the compliance rate was lower in academic hospitals than in non-academic hospitals (P = 0.016). In conclusion, overall, compliance rates were high; however, for many QIs, practice remains to be improved in at least some centers. Steroids are infrequently used concurrently with radiotherapy for malignant spinal cord compression.
  • Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.
    Sogo Oki; Yukitomo Ishi; Ryosuke Sawaya; Michinari Okamoto; Hiroaki Motegi; Zen-Ichi Tanei; Masumi Tsuda; Takashi Mori; Kentaro Nishioka; Hiromi Kanno-Okada; Hidefumi Aoyama; Shinya Tanaka; Shigeru Yamaguchi; Miki Fujimura
    Acta neurochirurgica, 166, 1, 263, 263, 12 Jun. 2024, [International Magazine]
    English, Scientific journal, BACKGROUND: With the recent advent of genetic testing, IDH-mutant glioma has been found among adult brainstem gliomas. However, the clinical outcome and prognosis of IDH-mutant brainstem gliomas in adults have not been elucidated. This study aimed to investigate the clinical outcome, radiological findings, and genetic features of adult patients with IDH-mutant diffuse brainstem gliomas. METHODS: Data from adult patients with brainstem glioma at Hokkaido University Hospital between 2006 and 2022 were retrospectively analyzed. Patient characteristics, treatment methods, genetic features, and prognosis were evaluated. RESULTS: Of 12 patients with brainstem glioma with proven histopathology, 4 were identified with IDH mutation. All patients underwent local radiotherapy with 54 Gray in 27 fractions combined with chemotherapy with temozolomide. Three patients had IDH1 R132H mutation and one had IDH2 R172G mutation. The median progression-free survival and overall survival were 68.4 months and 85.2 months, respectively, longer than that for IDH-wildtype gliomas (5.6 months and 12.0 months, respectively). At the time of initial onset, contrast-enhanced lesions were observed in two of the four cases in magnetic resonance imaging. CONCLUSION: As some adult brainstem gliomas have IDH mutations, and a clearly different prognosis from those with IDH-wildtype, biopsies are proactively considered to confirm the genotype.
  • EVALUATION OF THE ACTUAL DOSE DISTRIBUTION USING CBCT FOR ULTRA-HYPOFRACTIONATED INTENSITY MODULATED PROTON THERAPY IN PROSTATE CANCER
    Hiroshi Tamura; Keiji Nakazato; Takaaki Yoshimura; Hiroto Yoshimoto; Yuto Matsuo; Keiichi Magota; Seishin Takao; Taeko Matsuura; Takashi Mori; Kentaro Nishioka; Takayuki Hashimoto; Hidefumi Aoyama
    International Journal of Particle Therapy, 12, 100456, 100456, Elsevier BV, Jun. 2024
    Scientific journal
  • Clinical outcomes for olfactory neuroblastoma
    Akira Nakazono; Hiroaki Motegi; Masanobu Suzuki; Yuji Nakamaru; Shigeru Yamaguchi; Yukitomo Ishi; Satoshi Kano; Nayuta Tsushima; Aya Honma; Takayoshi Suzuki; Shogo Kimura; Seijiro Hamada; Jun Taguchi; Yasushi Shimizu; Takashi Mori; Koichi Yasuda; Hidefumi Aoyama; Ichiro Kinoshita; Miki Fujimura; Akihiro Homma
    Frontiers in Oncology, 14, Frontiers Media SA, 02 May 2024, [Peer-reviewed]
    Scientific journal, Background

    Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB.

    Methods

    A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data.

    Results

    Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS.

    Conclusion

    Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.
  • A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.
    Kentaro Nishioka; Takayuki Hashimoto; Takashi Mori; Yusuke Uchinami; Rumiko Kinoshita; Norio Katoh; Hiroshi Taguchi; Koichi Yasuda; Yoichi M Ito; Seishin Takao; Masaya Tamura; Taeko Matsuura; Shinichi Shimizu; Hiroki Shirato; Hidefumi Aoyama
    Advances in radiation oncology, 9, 5, 101464, 101464, May 2024, [International Magazine]
    English, Scientific journal, PURPOSE: In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer. METHODS AND MATERIALS: Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE. RESULTS: Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%). CONCLUSIONS: The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies.
  • A new predictive parameter for dose‐volume metrics in intensity‐modulated radiation therapy planning for prostate cancer: Initial phantom study
    Yuki Saito; Ryusuke Suzuki; Naoki Miyamoto; Kenneth Lee Sutherland; Takahiro Kanehira; Masaya Tamura; Takashi Mori; Kentaro Nishioka; Takayuki Hashimoto; Hidefumi Aoyama
    Journal of Applied Clinical Medical Physics, Apr. 2024, [Peer-reviewed]
    Scientific journal
  • Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
    Yusuke Uchinami; Koichi Yasuda; Hideki Minatogawa; Yasuhiro Dekura; Noboru Nishikawa; Rumiko Kinoshita; Kentaro Nishioka; Norio Katoh; Takashi Mori; Manami Otsuka; Naoki Miyamoto; Ryusuke Suzuki; Keiji Kobashi; Yasushi Shimizu; Jun Taguchi; Nayuta Tsushima; Satoshi Kano; Akihiro Homma; Hidefumi Aoyama
    Radiation oncology journal, 42, 1, 74, 82, Mar. 2024, [International Magazine]
    English, Scientific journal, PURPOSE: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival. RESULTS: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541). CONCLUSION: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.
  • 当院における転移性脳腫瘍への術後定位照射症例の検討
    高橋 周平; 森 崇; 打浪 雄介; 西岡 健太郎; 青山 英史; 茂木 洋晃; 山口 秀
    Japanese Journal of Radiology, 42, Suppl., 10, 10, (公社)日本医学放射線学会, Feb. 2024
    Japanese
  • Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan.
    Koichi Yasuda; Yusuke Uchinami; Satoshi Kano; Jun Taguchi; Daisuke Kawakita; Megumi Kitayama; Kentaro Nishioka; Takashi Mori; Fuki Koizumi; Yuri Fujii; Yasushi Shimizu; Keiji Kobashi; Seiichi Yoshimoto; Ken-Ichi Nibu; Akihiro Homma; Hidefumi Aoyama
    International journal of clinical oncology, 29 Dec. 2023, [Domestic magazines]
    English, Scientific journal, BACKGROUND: Whether concurrent chemotherapy with radiotherapy (CRT) is effective for elderly patients with head and neck cancer is a controversial topic. This study aimed to analyze the effectiveness of CRT vs. radiation therapy (RT) among elderly patients in Japan. METHODS: Data from the Head and Neck Cancer Registry of Japan were extracted and analyzed. Patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx who received definitive CRT or RT between 2011 and 2014 were included. RESULTS: CRT was administered to 78% of the 1057 patients aged ≥ 70 years and 67% of the 555 patients aged ≥ 75 years. For the patients aged ≥ 75 years, the overall survival (OS) rate was significantly better in the CRT group than in the RT group (P < 0.05), while the progression-free survival (PFS) rate was not significantly different (P > 0.05). The add-on effect of CRT was significantly poor in elderly patients (P < 0.05), and it was not a significant factor in the multivariate analysis for patients aged ≥ 75 years. After propensity score matching, there were no significant differences in the OS and PFS rates between the patients aged ≥ 70 years and those aged ≥ 75 years (all, P > 0.05). CONCLUSION: Although aggressive CRT is administered to elderly patients in Japan, its effectiveness is uncertain. Further prospective randomized trials are needed to verify whether CRT is superior to RT alone for elderly patients.
  • 北大病院放射線治療科関連施設における乳癌の放射線治療に関するアンケート結果リンパ節領域に対する照射について
    木下 留美子; 田口 大志; 高橋 周平; 宮崎 智彦; 森 崇; 西岡 健太郎; 橋本 孝之; 青山 英史
    北海道外科雑誌, 68, 2, 163, 164, 北海道外科学会, Dec. 2023
    Japanese
  • Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
    Yasuhiro Dekura; Koichi Yasuda; Hideki Minatogawa; Yusuke Uchinami; Nayuta Tsushima; Takayoshi Suzuki; Satoshi Kano; Takashi Mori; Kentaro Nishioka; Keiji Kobashi; Norio Katoh; Akihiro Homma; Hidefumi Aoyama
    Journal of radiation research, 10 Nov. 2023, [International Magazine]
    English, Scientific journal, The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.
  • The need of radiotherapy optimization for glioblastomas considering immune responses.
    Kentaro Nishioka; Shuhei Takahashi; Takashi Mori; Yusuke Uchinami; Shigeru Yamaguchi; Manabu Kinoshita; Masaaki Yamashina; Hajime Higaki; Katsuya Maebayashi; Hidefumi Aoyama
    Japanese journal of radiology, 18 Apr. 2023, [Peer-reviewed], [Domestic magazines]
    English, Scientific journal, Glioblastoma is the most common of malignant primary brain tumors and one of the tumors with the poorest prognosis for which the overall survival rate has not significantly improved despite recent advances in treatment techniques and therapeutic drugs. Since the emergence of immune checkpoint inhibitors, the immune response to tumors has attracted increasing attention. Treatments affecting the immune system have been attempted for various tumors, including glioblastomas, but little has been shown to be effective. It has been found that the reason for this is that glioblastomas have a high ability to evade attacks from the immune system, and that the lymphocyte depletion associated with treatment can reduce its immune function. Currently, research to elucidate the resistance of glioblastomas to the immune system and development of new immunotherapies are being vigorously carried out. Targeting of radiation therapy for glioblastomas varies among guidelines and clinical trials. Based on early reports, target definitions with wide margins are common, but there are also reports that narrowing the margins does not make a significant difference in treatment outcome. It has also been suggested that a large number of lymphocytes in the blood are irradiated by the irradiation treatment to a wide area in a large number of fractionations, which may reduce the immune function, and the blood is being recognized as an organ at risk. Recently, a randomized phase II trial comparing two types of target definition in radiotherapy for glioblastomas was conducted, and it was reported that the overall survival and progression-free survival were significantly better in a small irradiation field group. We review recent findings on the immune response and the immunotherapy to glioblastomas and the novel role of radiotherapy and propose the need to develop an optimal radiotherapy that takes radiation effects on the immune function into account.
  • Proton beam therapy for gliomas: a multicenter prospective registry study from all proton beam facilities in Japan
    Takashi Mori; Masashi Mizumoto; Katsuya Maebayashi; Kentaro Nishioka; Yoshiki Arakawa; Kazuhiko Kurozumi; Koichi Yasuda; Taisuke Sumiya; Hiroyasu Tamamura; Yoshitaka Sato; Takahiro Waki; Masaru Takagi; Yu Takada; Tomoaki Okimoto; Masao Murakami; Yasuhiro Kikuchi; Kazufumi Okada; Yoichi M Ito; Tetsuo Akimoto; Hidefumi Aoyama
    Journal of Radiation Research, Oxford University Press (OUP), 07 Apr. 2023, [Peer-reviewed], [Lead author]
    English, Scientific journal, Abstract

    We reviewed the outcomes of glioma patients enrolled in a prospective observational registry study of proton beam therapy (PBT) in Japan. The inclusion criteria were glioma patients registered in the Electronic Data Capture system, the Proton-net, between May 2016 and July 2019. Data on patient characteristics, treatments, late adverse events, survival status, recurrence and secondary tumors were extracted and statistically analyzed. The primary endpoint was the overall survival (OS) rate, and the secondary endpoints were the progression-free survival (PFS) rate and cumulative local recurrence rate (cLRR). Of the 65 primary brain tumor patients registered, 29 glioma patients from eight of 19 PBT facilities met the inclusion criteria. There were 19 glioblastoma patients, eight of other malignant gliomas, and two of low-grade gliomas. For glioblastomas, with a median follow-up period of 16 months, the median survival time was 21.2 months and the OS at 1, 2, 3 and 4 years were 77.4%, 44.9%, 23.9% and 23.9%, respectively. The median PFS period was 10.1 months, the 1, 2, 3 and 4-year PFS were 32.4%, 19.4%, 9.7% and 9.7%, respectively. The 1, 2, 3 and 4-year cLRR were 56.1%, 68.8%, 78.4 and 78.4%, respectively. Grade 3 brain necrosis was observed in two patients. No secondary tumor was observed. This is the first report on the current status of PBT for gliomas in Japan. For glioblastomas, the outcomes of PBT are estimated to be equivalent to historical data of photon therapy. The results of a prospective comparative evaluation of PBT and photon therapy are awaited.
  • Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
    Hajime Higaki; Kentaro Nishioka; Manami Otsuka; Noboru Nishikawa; Motoyasu Shido; Hideki Minatogawa; Yukiko Nishikawa; Rikiya Takashina; Takayuki Hashimoto; Norio Katoh; Hiroshi Taguchi; Rumiko Kinoshita; Koichi Yasuda; Takashi Mori; Yusuke Uchinami; Fuki Koizumi; Yoshihiro Fujita; Shuhei Takahashi; Takahiro Hattori; Noriaki Nishiyama; Hidefumi Aoyama
    Radiation oncology (London, England), 18, 1, 25, 25, 07 Feb. 2023, [Peer-reviewed], [International Magazine]
    English, Scientific journal, BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.
  • 肝細胞癌陽子線治療効果予測におけるADC値指標の検討
    藤田 祥博; 加藤 徳雄; 打浪 雄介; 田口 大志; 西岡 健太郎; 森 崇; 安田 耕一; 小泉 富基; 大塚 愛美; 高尾 聖心; 田村 昌也; Sutherland Kenneth; Khin Khin Tha; 伊藤 陽一; 青山 英史
    Japanese Journal of Radiology, 41, Suppl., 10, 10, (公社)日本医学放射線学会, Feb. 2023
    Japanese
  • Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer.
    Rumiko Kinoshita; Takashi Mitamura; Fumi Kato; Takahiro Hattori; Hajime Higaki; Shuhei Takahashi; Yoshihiro Fujita; Manami Otsuka; Fuki Koizumi; Yusuke Uchinami; Takashi Mori; Kentaro Nishioka; Takayuki Hashimoto; Yoichi M Ito; Hidemichi Watari; Hidefumi Aoyama
    Journal of radiation research, 64, 2, 463, 470, 03 Jan. 2023, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Most oncogenic human papilloma virus (HPV) genotypes stratify into two species, α-7 HPV and α-9 HPV. There are several studies that evaluate the relationship between HPV species and treatment outcomes and reports that HPV species is prognostic. The HPV genotyping was conducted using biopsy specimens which had been stored in these studies. We conducted the study using the HPV test performed by cytology specimens which is less invasive and more useful in clinical settings. This study enrolled 46 patients who received HPV genotyping before the definitive radiotherapy. The results of the HPV genotyping were classified into HPVα-7, HPVα-9 and negatives. Of the 46 patients, 10 were positive for HPVα-7, 21 positive for HPVα-9 and 15 were negative. The median follow-up period was 38 months (range 4-142). The HPVα-7, HPVα-9 and negative groups showed the 3-year overall survival (OS; 59.3%, 80.4% and 72.2% [P = 0.25]); local control (LC; 67.5%, 81% and 80% [P = 0.78]); pelvic control (PC) (50%, 81% and 72.7% [P = 0.032]); pelvic lymph node (PLN) control (78.7%, 95% and 92.3% [P = 0.012]); distant metastasis free (DMF) survival (50%, 75.4% and 42.8% [P = 0.098]); and progression free survival (PFS) rate of patients (30%, 66.7% and 38.9% [P = 0.085]), respectively. Patients with HPVα-7 showed statistically significant poorer PC than the HPVα-9 group, in multivariate analysis. This result is consistent with previous studies for HPV positive patients. The HPV negativity rate was higher in this study than in other studies and further work on this may be needed for clinical use.
  • Prostatic urinary tract visualization with super-resolution deep learning models.
    Takaaki Yoshimura; Kentaro Nishioka; Takayuki Hashimoto; Takashi Mori; Shoki Kogame; Kazuya Seki; Hiroyuki Sugimori; Hiroko Yamashina; Yusuke Nomura; Fumi Kato; Kohsuke Kudo; Shinichi Shimizu; Hidefumi Aoyama
    PloS one, 18, 1, e0280076, 2023, [Peer-reviewed], [International Magazine]
    English, Scientific journal, In urethra-sparing radiation therapy, prostatic urinary tract visualization is important in decreasing the urinary side effect. A methodology has been developed to visualize the prostatic urinary tract using post-urination magnetic resonance imaging (PU-MRI) without a urethral catheter. This study investigated whether the combination of PU-MRI and super-resolution (SR) deep learning models improves the visibility of the prostatic urinary tract. We enrolled 30 patients who had previously undergone real-time-image-gated spot scanning proton therapy by insertion of fiducial markers. PU-MRI was performed using a non-contrast high-resolution two-dimensional T2-weighted turbo spin-echo imaging sequence. Four different SR deep learning models were used: the enhanced deep SR network (EDSR), widely activated SR network (WDSR), SR generative adversarial network (SRGAN), and residual dense network (RDN). The complex wavelet structural similarity index measure (CW-SSIM) was used to quantitatively assess the performance of the proposed SR images compared to PU-MRI. Two radiation oncologists used a 1-to-5 scale to subjectively evaluate the visibility of the prostatic urinary tract. Cohen's weighted kappa (k) was used as a measure of agreement of inter-operator reliability. The mean CW-SSIM in EDSR, WDSR, SRGAN, and RDN was 99.86%, 99.89%, 99.30%, and 99.67%, respectively. The mean prostatic urinary tract visibility scores of the radiation oncologists were 3.70 and 3.53 for PU-MRI (k = 0.93), 3.67 and 2.70 for EDSR (k = 0.89), 3.70 and 2.73 for WDSR (k = 0.88), 3.67 and 2.73 for SRGAN (k = 0.88), and 4.37 and 3.73 for RDN (k = 0.93), respectively. The results suggest that SR images using RDN are similar to the original images, and the SR deep learning models subjectively improve the visibility of the prostatic urinary tract.
  • 強度変調回転照射法(VMAT)で術後照射を行った2例
    木下 留美子; 檜垣 朔; 藤田 祥博; 森 崇; 西岡 健太郎; 橋本 孝之; 青山 英史; 押野 智博; 高橋 将人; 加藤 扶美; 金平 孝博
    北海道外科雑誌, 67, 2, 162, 163, 北海道外科学会, Dec. 2022
    Japanese
  • Long-term consequences of residual lesions after chemoradiotherapy in patients with germinoma at onset.
    Shigeru Yamaguchi; Michinari Okamoto; Yukitomo Ishi; Ryosuke Sawaya; Hiroaki Motegi; Minako Sugiyama; Taisuke Harada; Noriyuki Fujima; Takashi Mori; Takayuki Hashimoto; Emi Takakuwa; Atsushi Manabe; Kohsuke Kudo; Hidefumi Aoyama; Miki Fujimura
    Journal of neurosurgery. Pediatrics, 1, 8, 09 Sep. 2022, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: In patients with intracranial germ cell tumors, residual lesions are sometimes observed after completion of primary chemoradiotherapy. Although salvage resection of these end-of-treatment residual lesions is recommended for patients with nongerminomatous germ cell tumors, the necessity of early salvage resection for those with germinoma is not clear. The aim of this study was to investigate the frequency of residual germinoma lesions after primary chemoradiotherapy, as well as their management, long-term consequences, and prognosis. METHODS: The authors retrospectively reviewed patients who were primarily treated for germinoma between 2002 and 2021. Residual lesions were evaluated with MRI with and without contrast enhancement within 2 weeks after chemoradiotherapy. The decision to perform salvage resection of residual lesions was at the discretion of the treating physicians. The change in appearance of residual lesions was assessed with serial MRI. Overall survival (OS), progression-free survival (PFS), and recurrence pattern were also investigated. RESULTS: Sixty-nine patients were treated with chemoradiotherapy for germinoma, with a mean follow-up period of 108 months. Residual lesions were radiologically observed in 30 patients (43.5%). Among these, 5 patients (3 with pineal lesions and 2 with basal ganglia lesions) underwent salvage resection. Pathological examination revealed teratomatous components in 3 patients, whereas no tumoral components were identified in 2 patients. One patient with a basal ganglia lesion showed worsening of hemiparesis postoperatively. The remaining 25 patients received watchful observation without surgical intervention. Chronological periodic radiological change in residual lesions was evaluated in 21 patients. One year after primary treatment, the size of the residual lesions was stable and had decreased in 10 and 11 patients, respectively. None of the lesions increased in size. The 10-year PFS and OS rates were 96.7% and 97.3% in patients without residual lesions (n = 39), and 87.1% and 100% in patients with residual lesions (n = 30), respectively. Presence of residual lesions had no significant effect on PFS or OS. All recurrences occurred at distant sites or via dissemination without progression of the primary tumor site, regardless of the presence of residual lesion. CONCLUSIONS: End-of-treatment residual lesions are not rare in patients with germinoma, and these residual lesions seldom show progression. Because of the potential risk of surgical complications, the indication for early salvage surgery for residual lesions should be carefully determined. Watchful observation is recommended for the majority of these cases.
  • 放射線治療を中心としたがん治療について-最近の変化と将来- 膠芽腫に対する免疫反応を考慮した照射野最適化の必要性
    西岡 健太郎; 高橋 周平; 森 崇; 打浪 雄介; 山口 秀; 木下 学; 山品 将祥; 前林 勝也; 青山 英史
    日本医学放射線学会秋季臨床大会抄録集, 58回, S345, S345, (公社)日本医学放射線学会, Aug. 2022
    Japanese
  • 放射線治療を中心としたがん治療について-最近の変化と将来- 膠芽腫に対する免疫反応を考慮した照射野最適化の必要性
    西岡 健太郎; 高橋 周平; 森 崇; 打浪 雄介; 山口 秀; 木下 学; 山品 将祥; 前林 勝也; 青山 英史
    日本医学放射線学会秋季臨床大会抄録集, 58回, S345, S345, (公社)日本医学放射線学会, Aug. 2022
    Japanese
  • 【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と放射線治療
    安田 耕一; 志藤 元泰; 小泉 富基; 高橋 周平; 藤田 祥博; 大塚 愛美; 宮崎 智彦; 西川 昇; 打浪 雄介; 森 崇; 西岡 健太郎; 木下 留美子; 田口 大志; 加藤 徳雄; 橋本 孝之; 青山 英史
    腫瘍内科, 30, 1, 23, 28, (有)科学評論社, Jul. 2022
    Japanese
  • 北海道大学病院放射線治療科関連施設における子宮頸癌に対する根治放射線治療に関するアンケート結果について
    木下 留美子; 打浪 雄介; 高橋 周平; 小泉 富基; 森 崇; 西岡 健太郎; 田口 大志; 橋本 孝之; 高邑 明夫; 西岡 井子; 北原 利博; 土屋 和彦; 井上 哲也; 有本 卓郎; 出倉 康裕; 米坂 祥朗; 鈴木 恵士郎; 川島 和之; 小野寺 俊輔; 喜多村 圭; 長谷川 雅一; 鬼丸 力也; 富田 雅義; 池田 潤; 西山 典明; 青山 英史
    北海道放射線医学雑誌, 2, 13, 18, (NPO)メディカルイメージラボ, Mar. 2022, [Peer-reviewed]
    Japanese
  • HyperArcを用いた多発性脳転移腫瘍に対する脳定位放射線治療中の各標的の位置ずれに関する検討
    山田 亮太; 吉村 高明; 若林 倭; 金平 孝博; 森 崇; 西岡 健太郎; 青山 英史
    日本放射線技術学会総会学術大会予稿集, 78回, 161, 162, (公社)日本放射線技術学会, Mar. 2022
    Japanese
  • 再照射 小児がんに対する陽子線再照射
    橋本 孝之; 森 崇; 西岡 健太郎; 打浪 雄介; 安田 耕一; 木下 留美子; 田口 大志; 加藤 徳雄; 清水 伸一; 青山 英史
    日本小児血液・がん学会雑誌, 58, 2, 89, 93, (一社)日本小児血液・がん学会, Aug. 2021
    Japanese
  • Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
    Koichi Yasuda; Hideki Minatogawa; Yasuhiro Dekura; Seishin Takao; Masaya Tamura; Nayuta Tsushima; Takayoshi Suzuki; Satoshi Kano; Takatsugu Mizumachi; Takashi Mori; Kentaro Nishioka; Motoyasu Shido; Norio Katoh; Hiroshi Taguchi; Noriyuki Fujima; Rikiya Onimaru; Isao Yokota; Keiji Kobashi; Shinichi Shimizu; Akihiro Homma; Hiroki Shirato; Hidefumi Aoyama
    Journal of radiation research, 62, 2, 329, 337, 10 Mar. 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.
  • Diagnostic Capability of Cerebrospinal Fluid-Placental Alkaline Phosphatase Value in Intracranial Germ Cell Tumor.
    Michinari Okamoto; Shigeru Yamaguchi; Yukitomo Ishi; Hiroaki Motegi; Takashi Mori; Takayuki Hashimoto; Yukayo Terashita; Shinsuke Hirabayashi; Minako Sugiyama; Akihiro Iguchi; Yuko Cho; Atsushi Manabe; Kiyohiro Houkin
    Oncology, 99, 1, 23, 31, 2021, [Peer-reviewed], [International Magazine]
    English, Scientific journal, OBJECTIVE: Most types of intracranial germ cell tumors (IGCTs) are sensitive to chemoradiation. However, biopsy specimens are usually small and thus cannot be used for obtaining an accurate pathological diagnosis. Recently, the cerebrospinal fluid (CSF) placental alkaline phosphatase (PLAP) value has been considered a new biomarker of IGCTs. The present study aimed to evaluate the discriminatory characteristics of the CSF-PLAP value upon diagnosis and at the time of recurrence in patients with IGCTs. METHODS: Between 2015 and 2019, this study included 37 patients with tumors located in the intraventricular and/or periventricular region. The CSF-PLAP level was assessed before the patients received any treatment. The PLAP level was evaluated during and after first-line chemoradiotherapy in 7 patients with IGCTs. The CSF-PLAP values were compared according to histological diagnosis, and the correlation between these values and radiographical features was assessed. The CSF-PLAP values of 6 patients with IGCTs with suspected recurrence were evaluated based on neuroimaging findings. RESULTS: The CSF-PLAP values were significantly higher in patients with IGCTs than in those with other types of brain tumor (n = 19 vs. 18; median: 359.0 vs. <8.0 pg/mL). The specificity and sensitivity were 88 and 95%, respectively, with a cutoff value of 8.0 pg/mL. In patients with IGCT, the CSF-PLAP value was higher in patients with germinoma than in those with nongerminomatous germ cell tumors (n = 12 vs. 7; median: 415.0 vs. 359.0 pg/mL). Regarding the time course, the CSF-PLAP value decreased to below the detection limit after the reception of first-line chemoradiotherapy in all 7 patients. A significant correlation was observed between the initial CSF-PLAP value and the tumor reduction volume after receiving first-line chemoradiotherapy (p < 0.0003, R2 = 0.6165, logY = 1.202logX - 1.727). Among the patients with suspected IGCT recurrence (n = 6), the CSF-PLAP value was high in patients with recurrence (n = 3; median: 259.0 pg/mL), and that in patients (n = 3) without recurrence was below the lower detection limit. CONCLUSIONS: The CSF-PLAP level is a useful biomarker during the initial diagnosis of IGCTs and at the time of recurrence. It may be associated with the volume of germinomatous components of tumors.
  • 画像誘導治療の今後について 画像誘導陽子線治療の将来展望
    田口 大志; 橋本 孝之; 加藤 徳雄; 木下 留美子; 安田 耕一; 西岡 健太郎; 森 崇; 打浪 雄介; 宮本 直樹; 高尾 聖心; 清水 伸一; 青山 英史
    日本癌治療学会学術集会抄録集, 58回, SY14, 3, (一社)日本癌治療学会, Oct. 2020
    English
  • Clinical experience of craniospinal intensity-modulated spot-scanning proton therapy using large fields for central nervous system medulloblastomas and germ cell tumors in children, adolescents, and young adults
    Takayuki Hashimoto; Shinichi Shimizu; Seishin Takao; Shunsuke Terasaka; Akihiro Iguchi; Hiroyuki Kobayashi; Takashi Mori; Takaaki Yoshimura; Yuto Matsuo; Masaya Tamura; Taeko Matsuura; Yoichi M. Ito; Rikiya Onimaru; Hiroki Shirato
    Journal of radiation research, 60, 4, 527, 537, 01 Jul. 2019, [Peer-reviewed], [International Magazine]
    Scientific journal
  • 脳動静脈奇形SRS後に妊娠,分娩に至った1例
    森 崇; 鬼丸 力也; 白土 博樹; 細川 亜美; 森川 守; 水上 尚典; 中山 若樹; 西村 あや子
    Japanese Journal of Radiology, 37, Suppl., 14, 14, (公社)日本医学放射線学会, Feb. 2019
    Japanese
  • Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system.
    Nishioka K; Prayongrat A; Ono K; Onodera S; Hashimoto T; Katoh N; Inoue T; Kinoshita R; Yasuda K; Mori T; Onimaru R; Shirato H; Shimizu S
    Journal of radiation research, 59, suppl_1, i63, i71, Mar. 2018, [Peer-reviewed], [International Magazine]
    English, Scientific journal, This is a report of a single-institution prospective study evaluating the safety of a spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy (PBT) system. Data collection was performed for 56 patients with 59 treatment sites who received proton beam therapy at Hokkaido University Hospital between March 2014 and July 2015. Forty-one patients were male and 15 were female. The median age was 66 years. The primary lesion sites were prostate (n = 17), bone/soft tissue (n = 10), liver (n = 7), lung (n = 6), central nervous system (n = 5), colon (n = 2), pancreas (n = 2), kidney (n = 2) and others (n = 5). Chemotherapy was administered in 11 patients. The prescribed total dose was from 20 to 76 GyE (Radiobiological equivalent dose, RBE = 1.1), with the median dose of 65 GyE in 4 to 35 fractions. No PBT-related Common Terminology Criteria for Adverse Events Grade 4 or 5 toxicities were observed; the incidence of early PBT-related Grade 4 adverse events was 0% (95% confidence interval 0 to 6.38%). The most common Grade 3 toxicities were hematologic toxicity (12.5%) unlikely to be related to the PBT. One patient developed a left femoral neck fracture (Grade 3) at 14.5 months after PBT for chondrosarcoma of the left pelvis. The pathological findings showed no other malignancies, suggesting that it was possibly related to the PBT. In conclusion, the spot-scanning dedicated, synchrotron-based PBT system is feasible, but further studies on its long-term safety and efficacy are warranted.
  • 【悪性脊椎脊髄腫瘍に対する治療】 原発性悪性脊椎脊髄腫瘍に対する放射線治療
    鬼丸 力也; 森 崇; 加藤 徳雄; 関 俊隆; 白土 博樹
    脊椎脊髄ジャーナル, 30, 7, 673, 676, (株)三輪書店, Jul. 2017
    Japanese
  • 乳房温存術後接線照射後にFitz-Hugh-Curtis症候群様の肝周囲炎を来した1例
    出倉 康裕; 森 崇; 西川 由記子; 木下 留美子; 橋本 孝之; 白土 博樹; 西岡 健太郎; 清水 伸一; 細田 充主; 山下 啓子
    Japanese Journal of Radiology, 35, Suppl., 4, 4, (公社)日本医学放射線学会, Feb. 2017
    Japanese
  • Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography
    Takashi Mori; Rikiya Onimaru; Shunsuke Onodera; Kazuhiko Tsuchiya; Koichi Yasuda; Hiromitsu Hatakeyama; Hiroyuki Kobayashi; Shunsuke Terasaka; Akihiro Homma; Hiroki Shirato
    RADIATION ONCOLOGY, 10, 88, Apr. 2015, [Peer-reviewed], [Lead author], [International Magazine]
    English, Scientific journal
  • 骨転移をきたした小脳膠芽腫の1例
    湊川 英樹; 森 崇; 鬼丸 力也; 小野寺 俊輔; 白土 博樹; 東海林 菊太郎; 吉田 道春; 小林 浩之; 寳金 清博; 菅野 宏美; 田中 伸哉
    Japanese Journal of Radiology, 33, Suppl., 4, 4, (公社)日本医学放射線学会, Feb. 2015
    Japanese
  • Three-dimensional conformal fractionated radiotherapy for spinal schwannoma with a paravertebral or an intraosseous component
    Onimaru R; Hida K; Takeda N; Onodera S; Nishikawa Y; Mori T; Shirato H
    Jpn J Radiol, 33, 12, 757, 763, Springer, 2015, [Peer-reviewed], [International Magazine]
    English, Introduction: We retrospectively evaluated the efficacy of three-dimensional conformal radiotherapy (3D-CRT) for spinal schwannoma. Methods: Nine patients with spinal schwannoma were treated with 3D-CRT. All patients had a paravertebral or intraosseous component. Tumor sizes ranged from 0.8 to 8.7 cm, with a median of 3.5 cm. The prescribed dose was 50 Gy in 25 fractions at the isocenter, except for 1 patient who received 66 Gy in 33 fractions for a large sacral tumor. The follow-up period ranged from 20 to 137 months, with a median of 72 months. Results: Tumor shrinkage within 3 mm occurred in 4 patients and tumor expansion within 3 mm occurred in 3. One tumor showed neither expansion nor shrinkage at the last follow-up. One patient experienced transient expansion by 8 mm in diameter at 12 months after the completion of radiotherapy (35-43 mm), and then the tumor size remained unchanged for 7 years. No severe late toxicity a parts per thousand yen grade 3 was observed. Conclusions: Only 1 of 9 tumors showed transit expansion over 3 mm after 3D-CRT, and severe late radiation toxicity was not observed. Use of 3D-CRT should be considered a treatment option for spinal schwannoma.
■ Other Activities and Achievements
■ Syllabus
  • 医学総論, 2024年, 博士後期課程, 医学研究科
  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医理工学連携総論, 2024年, 修士課程, 医理工学院
  • 医理工連携放射線腫瘍学, 2024年, 修士課程, 医理工学院
  • 医療機器臨床研究特論, 2024年, 修士課程, 医理工学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院
  • 放射線腫瘍学, 2024年, 学士課程, 医学部